CD274 and glioblastoma: First, we extracted data from three cohorts involving anti-PD-L1 (IMvigor210, urothelial cancer), anti-PD-1 (GSE78220, melanomas) and anti-PD-1 (GSE154795, GSE121810, GBM) immunotherapies, respectively.